Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Clin Cancer Res. 2016 Oct 17;23(9):2367–2373. doi: 10.1158/1078-0432.CCR-16-2154-T

Figure 1.

Figure 1

Clinical history of an exceptional responder to combined MAPK and PI3K inhibition. A, Graphical description of clinical events. B, Radiographic documentation of response. The patient’s tumor continued to grow through everolimus and dabrafenib monotherapies individually. When combined, the patient’s tumor showed a dramatic response.